New gel treatment aims to reduce 'Off' time in advanced Parkinson's

NCT ID NCT07313176

Recruiting now Disease control Sponsor: Britannia Pharmaceuticals Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 03, 2026 · Last updated May 17, 2026 · Updated 22 times

Summary

This study follows about 215 adults with advanced Parkinson's disease who are switching from a subcutaneous medication to LECIGON, an intestinal gel. The main goal is to see if LECIGON reduces daily 'OFF' time (when symptoms return) after 12 months. Participants will be monitored in routine care, and the study does not test a cure but aims to better control symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Complejo Hospitalario Universitario de A Coruña (CHUAC)
RECRUITING

A Coruña, 15006, Spain

Contact Phone: •••-•••-•••• Email: •••••@•••••
Virgen del Rocío University Hospital
RECRUITING

Seville, Av. Manuel Siurot, S/n, 41013, Spain

Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED PARKINSON DISEASE